AstraZeneca plc  

(Public, LON:AZN)   Watch this stock  
Find more results for AZN
+35.00 (0.79%)
May 22 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,439.00 - 4,489.50
52 week 4,075.00 - 4,931.68
Open 4,454.00
Vol / Avg. 1.92M/2.74M
Mkt cap 55.24B*
P/E 69.08
Div/yield 125.00/3.99*
EPS 0.65*
Shares 1.26B
Beta     -
Inst. own     -
Jul 30, 2015
Q2 2015 AstraZeneca PLC Earnings Release - 8:00AM GMT+1 - Add to calendar
Apr 24, 2015
AstraZeneca PLC Annual Shareholders Meeting
Apr 24, 2015
Q1 2015 AstraZeneca PLC Earnings Call - Webcast
Apr 24, 2015
Innate Pharma SA and AstraZeneca PLC Announce Global Agreement for IPH2201 in Immuno-oncology Call
Apr 24, 2015
Q1 2015 AstraZeneca PLC Earnings Release
Mar 25, 2015
AstraZeneca PLC at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 16, 2015
AstraZeneca PLC Investor Science Conference Call ACC 2015

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 9.11% 4.73%
Operating margin 15.40% 8.19%
EBITD margin - 29.87%
Return on average assets 3.94% 2.16%
Return on average equity 12.07% 5.75%
Employees 57,500 -
CDP Score - 93 A


- Legal Department, 2 Kingdom Street
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


AstraZeneca PLC is the United Kingdom-based global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca’s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities across the world. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 55
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 61
Ruud Dobber Executive Vice President, Europe
Caroline Hempstead Interim Executive Vice-President, Human Resources & Corporate Affairs
Paul Hudson Executive Vice President, North America
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Mark Mallon Executive Vice President, International
Briggs Morrison Executive Vice President - Global Medicines Development
Menelas Pangalos Executive Vice President - Innovative Medicines
David Smith Executive Vice President - Operations and Information Services